SEC Form 3 · accession 0001615774-19-000102
Intec Pharma Ltd. · NTEC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony J Maddaluna
Director
Period of report
Jan 1, 2019
Accepted (ET)
Jan 2, 2019 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001638381
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | holding | — | — | — | 28,570 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.44 | holding | — | — | — | — | Jun 28, 2025 | Ordinary Shares | 20,000 | — | D |
Explanation of responses
- F1The stock option vested and became exercisable as to one-third of the total shares on December 11, 2018 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through December 11, 2020.
Remarks
The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.